185 related articles for article (PubMed ID: 15823902)
21. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
[TBL] [Abstract][Full Text] [Related]
22. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis.
Griffiths CE; Finlay AY; Fleming CJ; Barker JN; Mizzi F; Arsonnaud S
J Dermatolog Treat; 2006; 17(2):90-5. PubMed ID: 16766333
[TBL] [Abstract][Full Text] [Related]
23. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis.
Feldman SR; Koo JY; Johnson LA; Preston NJ
Cutis; 2009 Oct; 84(4 Suppl):25-32. PubMed ID: 19916299
[TBL] [Abstract][Full Text] [Related]
24. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis.
Mazzotta A; Esposito M; Carboni I; Schipani C; Chimenti S
J Dermatolog Treat; 2007; 18(2):84-7. PubMed ID: 17520464
[TBL] [Abstract][Full Text] [Related]
25. The effect of alefacept on T-cell subsets and cells expressing NK receptors in lesional psoriatic skin: the effects of monotherapy and combination treatment with calcipotriol.
Vissers WH; van Duijnhoven M; van Erp PE; de Jong EM; van de Kerkhof PC
J Dermatolog Treat; 2008; 19(6):344-50. PubMed ID: 19016104
[TBL] [Abstract][Full Text] [Related]
26. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis.
Housman TS; Keil KA; Mellen BG; McCarty MA; Fleischer AB; Feldman SR
J Am Acad Dermatol; 2003 Jul; 49(1):79-82. PubMed ID: 12833013
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
Lee CS; Koo J
J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
[TBL] [Abstract][Full Text] [Related]
28. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse.
van der Vleuten CJ; van Vlijmen-Willems IM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 1999; 291(7-8):390-5. PubMed ID: 10482007
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis.
Liao YH; Jee SH; Sheu BC; Huang YL; Tseng MP; Hsu SM; Tsai TF
Br J Dermatol; 2006 Aug; 155(2):318-24. PubMed ID: 16882169
[TBL] [Abstract][Full Text] [Related]
30. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
Andres P; Poncet M; Farzaneh S; Soto P
J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
[TBL] [Abstract][Full Text] [Related]
31. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement.
Ohshima A; Takigawa M; Tokura Y
Eur J Dermatol; 2001; 11(5):410-5. PubMed ID: 11525946
[TBL] [Abstract][Full Text] [Related]
32. Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis.
Goedkoop AY; de Rie MA; Picavet DI; Kraan MC; Dinant HJ; van Kuijk AW; Tak PP; Bos JD; Teunissen MB
Arch Dermatol Res; 2004 Apr; 295(11):465-73. PubMed ID: 14968366
[TBL] [Abstract][Full Text] [Related]
33. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
[TBL] [Abstract][Full Text] [Related]
34. Combination topical therapy for the treatment of psoriasis.
Del Rosso Do JQ
J Drugs Dermatol; 2006 Mar; 5(3):232-4. PubMed ID: 16573255
[TBL] [Abstract][Full Text] [Related]
35. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
Jarratt M; Breneman D; Gottlieb AB; Poulin Y; Liu Y; Foley V
J Drugs Dermatol; 2004; 3(4):367-73. PubMed ID: 15303780
[TBL] [Abstract][Full Text] [Related]
36. Topical preparations for the treatment of psoriasis: results of a retrospective study over 15 years.
Zampetti A; Barone A; Antuzzi D; Amerio P; Tulli A; Feliciani C; Amerio P
J Dermatolog Treat; 2008; 19(3):134-40. PubMed ID: 18569269
[TBL] [Abstract][Full Text] [Related]
37. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.
Swinkels OQ; Prins M; Kucharekova M; de Boo T; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
Br J Dermatol; 2002 Apr; 146(4):621-6. PubMed ID: 11966693
[TBL] [Abstract][Full Text] [Related]
38. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Fransson J; Ros AM
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):326-32. PubMed ID: 16313245
[TBL] [Abstract][Full Text] [Related]
39. Clobetasol propionate for psoriasis: are ointments really more potent?
Warino L; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2006 Jun; 5(6):527-32. PubMed ID: 16774104
[TBL] [Abstract][Full Text] [Related]
40. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes.
Koo J; Blum RR; Lebwohl M
J Am Acad Dermatol; 2006 Oct; 55(4):637-41. PubMed ID: 17010744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
